1.A case of myelodysplastic syndrome with a der(1;18)(q10;q10) translocation.
Blood Research 2014;49(2):132-134
No abstract available.
Myelodysplastic Syndromes*
2.Azathioprine-induced Myelodysplasia Mimicking Myelodysplastic Syndrome
The Ewha Medical Journal 2019;42(3):46-47
No abstract available.
Myelodysplastic Syndromes
3.Methotrexate-induced myelodysplasia mimicking myelodysplastic syndrome.
Yuuki KAWASE ; Masashi OHE ; Haruki SHIDA ; Tetsuya HORITA ; Ken FURUYA ; Satoshi HASHINO
Blood Research 2018;53(4):268-268
No abstract available.
Myelodysplastic Syndromes*
4.ALG treatment of hypoplastic myelodysplastic syndrome.
Hwan Jun CHOI ; Seon Ju PARK ; Min Chul KIM ; Jae Who PARK ; Si Rhae LEE ; Sook Ja PARK
Korean Journal of Hematology 1991;26(2):379-384
No abstract available.
Myelodysplastic Syndromes*
5.Copper deficiency mimicking myelodysplastic syndrome.
Blood Research 2016;51(4):217-219
No abstract available.
Copper*
;
Myelodysplastic Syndromes*
6.Classifications and prognostic scoring systems in myelodysplastic syndrome.
Korean Journal of Medicine 2006;70(3):243-245
No abstract available.
Classification*
;
Myelodysplastic Syndromes*
7.Dry Dressing for Epidermal Sloughing after Subcutaneous Azacitidine Injection in a Myelodysplastic Syndrome.
Jun Yong LEE ; Hyunwook JUNG ; Ho KWON ; Sung No JUNG
Archives of Plastic Surgery 2014;41(4):425-426
No abstract available.
Azacitidine*
;
Bandages*
;
Myelodysplastic Syndromes*
8.Dysplastic eosinophils in myelodysplastic syndrome: association with complex karyotypes.
Blood Research 2016;51(2):75-75
No abstract available.
Eosinophils*
;
Karyotype*
;
Myelodysplastic Syndromes*
10.Recent advances in therapy of myelodysplastic syndromes.
Journal of Experimental Hematology 2012;20(6):1522-1525
Myelodysplastic syndrome (MDS) is a group of highly heterogeneous clonal disorders of myeloid hematopoietic stem cells, frequently characterized by bone marrow dysplasia and increased risks of transformation into acute myeloid leukemia. In recent years, several advances have been acquired in the treatment of MDS. Allogeneic hematopoietic stem cell transplantation is still the only way to make MDS to be long-term remission and even cure. And as for the use of drug, besides lenalidomide, decitabine and azacitidine approved by FDA, other medicines such as RAP-536, HDAC inhibitor, infliximab and combination therapy have also been used. This article focuses attention on the recent advances of the MDS treatment in hope of better understanding the present therapeutic status for MDS.
Humans
;
Myelodysplastic Syndromes
;
therapy
Result Analysis
Print
Save
E-mail